- Home
- GOSS vs CIO Comparison
GOSS vs CIO Comparison
Compare GOSS & CIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- CIO
- Stock Information
- Founded
- GOSS 2015
- CIO 2013
- Country
- GOSS United States
- CIO Canada
- Employees
- GOSS N/A
- CIO N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- CIO Real Estate Investment Trusts
- Sector
- GOSS Health Care
- CIO Real Estate
- Exchange
- GOSS Nasdaq
- CIO Nasdaq
- Market Cap
- GOSS 212.9M
- CIO 230.9M
- IPO Year
- GOSS 2019
- CIO 2014
- Fundamental
- Price
- GOSS $0.81
- CIO $5.43
- Analyst Decision
- GOSS Strong Buy
- CIO
- Analyst Count
- GOSS 5
- CIO 0
- Target Price
- GOSS $9.20
- CIO N/A
- AVG Volume (30 Days)
- GOSS 2.3M
- CIO 396.2K
- Earning Date
- GOSS 11-07-2024
- CIO 10-31-2024
- Dividend Yield
- GOSS N/A
- CIO 7.34%
- EPS Growth
- GOSS N/A
- CIO N/A
- EPS
- GOSS N/A
- CIO N/A
- Revenue
- GOSS $105,322,000.00
- CIO $173,528,000.00
- Revenue This Year
- GOSS N/A
- CIO N/A
- Revenue Next Year
- GOSS N/A
- CIO $0.90
- P/E Ratio
- GOSS N/A
- CIO N/A
- Revenue Growth
- GOSS N/A
- CIO N/A
- 52 Week Low
- GOSS $0.50
- CIO $4.02
- 52 Week High
- GOSS $1.60
- CIO $6.63
- Technical
- Relative Strength Index (RSI)
- GOSS 49.87
- CIO 45.52
- Support Level
- GOSS $0.76
- CIO $5.20
- Resistance Level
- GOSS $0.88
- CIO $5.73
- Average True Range (ATR)
- GOSS 0.08
- CIO 0.19
- MACD
- GOSS 0.01
- CIO -0.05
- Stochastic Oscillator
- GOSS 30.48
- CIO 29.28
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About CIO City Office REIT Inc.
City Office REIT Inc is a real estate investment trust. It is focused on acquiring, owning, and operating high-quality office properties located predominantly in Sun Belt markets. The principal objective of the company is to provide attractive risk-adjusted returns to its investors over the long-term through a combination of dividends and capital appreciation. The company owns office buildings in the metropolitan areas of Dallas, Denver, Orlando, Phoenix, Portland, Raleigh, San Diego, Seattle, and Tampa.